The vaccine uses live-attenuated technology and is sprayed into the nasal cavity, stimulating three types of immune response: mucosal, systemic, and cellular immunity.
According to VNVC, the vaccine provides up to 88% protection against influenza strains similar to those included in the vaccine.
The nasal spray vaccine is a step forward in the development of needle-free disease prevention solutions. It has been introduced in 34 countries and territories, with more than 200 million doses distributed worldwide.
